The article by Cruickshank et al. points out that HPV testing could be valuable in identifying a small portion of women still at risk after 50 years for the developing of cervical cancer (1) . The proposed changes for screening would serve the women more appropriately and use health care resources more efficiently. However, we propose a few suggestions. There should not only be screened for HPV16, but also for other high-risk HPV types like 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. The latter types are also well known for their relationship with invasive carcinoma of the cervix (2) . Between July 2000 and December 2002, the Laboratory of Clinical Pathology (Antwerp, Belgium) received 200,000 thin-layer cervical cytology preparations for cytologic evaluation from women in Flanders (Belgium). Using an algorithm for HPV testing based on MY9/11 consensus primers and type-specific PCRs (3) , 4095 samples were tested for the presence of 14 different oncogenic HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68).
valence of other oncogenic HPV subtype types in Flanders, restricting HPV screening to HPV 16 or 18 testing alone would be not sufficient. An extension of the number of types to be screened for at the age of 50 is therefore necessary. A reduction in the number of women screened would not only mean a reduction in costs, but also a reduction in the induced psychological stress of the screening This economic benefit would be warmly welcomed in the times of increased health costs and the decreased medical facilities.
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